Literature DB >> 17303434

Allogeneic hematopoietic stem cell transplantation in the elderly.

Michael Y Shapira1, P Tsirigotis, I B Resnick, R Or, A Abdul-Hai, S Slavin.   

Abstract

The development of reduced intensity or non-myeloablative conditioning (NST) in preparation for allogeneic stem cell transplantation (SCT) revolutionized the field and led to reconsideration of the dogma of upper age limit that was set up by the transplant centers as an eligibility parameter. Analysis of the literature data showed that NST regimens are associated with decreased transplant related mortality, and graft-versus-host disease, in comparison with standard myeloablative conditioning, in patients above the age of 50-55 years, or in younger patients with significant comorbidities. However we have to mention, that our considerations are based on the retrospective analysis of the literature data, and that well controlled prospective randomized studies are needed in order to definitely assess the role of NST. Comorbidity indices might be proved as the most important parameters for the choice of the most proper regimen for each patient in need and should be included in future trials.

Entities:  

Mesh:

Year:  2007        PMID: 17303434     DOI: 10.1016/j.critrevonc.2007.01.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  The benefit of exercise in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Shinichiro Morishita; Atsuhiro Tsubaki; Kazuki Hotta; Jack B Fu; Shigeo Fuji
Journal:  J Int Soc Phys Rehabil Med       Date:  2019-05-22

2.  Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation.

Authors:  Shivtia Trop-Steinberg; Yehudith Azar; Rachel Bringer; Reuven Or
Journal:  Clin Exp Med       Date:  2014-08-07       Impact factor: 3.984

3.  Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI.

Authors:  Christian Späth; Christoph Busemann; William H Krüger
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

Review 4.  Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.

Authors:  Basem M William; Marcos de Lima
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

5.  Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Authors:  M Pohlen; C Groth; T Sauer; D Görlich; R Mesters; C Schliemann; G Lenz; C Müller-Tidow; T Büchner; W E Berdel; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

Review 6.  Non-myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Nonniekaye Shelburne; Margaret Bevans
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

7.  Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates.

Authors:  Holly M Holmes; Jude K A Des Bordes; Partow Kebriaei; Sriram Yennu; Richard E Champlin; Sergio Giralt; Supriya G Mohile
Journal:  J Geriatr Oncol       Date:  2014-05-14       Impact factor: 3.599

8.  Allogeneic stem cell transplantation for refractory adult T-cell leukemia using a non-T-cell-depleted HLA-incompatible family donor graft, with reference to the grown-up child donor to parent recipient setting: report of a pilot study.

Authors:  Hiroshi Fujiwara; Atsuo Ozaki; Makoto Yoshimitsu; Heiichiro Hamada; Izumi Masamoto; Kakushi Matsushita; Masaki Yasukawa; Chuwa Tei
Journal:  Int J Hematol       Date:  2008-02-21       Impact factor: 2.319

Review 9.  Oral complications in hematopoietic stem cell recipients: the role of inflammation.

Authors:  T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema
Journal:  Mediators Inflamm       Date:  2014-04-10       Impact factor: 4.711

10.  Oral health-related quality of life of patients with oral chronic graft-versus-host disease.

Authors:  Juliette Stolze; Marlou Boor; Mette D Hazenberg; Henk S Brand; Judith E Raber-Durlacher; Alexa M G A Laheij
Journal:  Support Care Cancer       Date:  2021-04-21       Impact factor: 3.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.